Patents by Inventor Kathrin S. Michelsen

Kathrin S. Michelsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY
    Publication number: 20220363745
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Application
    Filed: March 22, 2022
    Publication date: November 17, 2022
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Signature of TL1A (TNFSF15) signaling pathway
    Patent number: 11312768
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: April 26, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY
    Publication number: 20200216526
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TL17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Application
    Filed: April 18, 2019
    Publication date: July 9, 2020
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Signature of TL1A (TNFSF15) signaling pathway
    Patent number: 10316083
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 11, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • SIGNATURE OF TL1A (TNFSF15) SIGNALING PATHWAY
    Publication number: 20160215046
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Application
    Filed: July 18, 2014
    Publication date: July 28, 2016
    Applicant: Cedars-Sinai Medical Center
    Inventors: Kathrin S. Michelsen, Stephan R. Targan